New and updated preclinical data presented at the American Society of Hematology Annual Meeting in New Orleans, by: Affimed, Asher Biotherapeutics, Disc Medicine, Keros Therapeutics, Kymera Therapeutics, Neoleukin Therapeutics, NGM Biopharmaceuticals, Oric Pharmaceuticals, Salarius Pharmaceuticals, Vincerx Pharma.
Researchers from Tubulis GmbH presented preclinical data for a CD30-targeting antibody-drug conjugate (ADC), TUB-010, being developed as a potential anticancer immunotherapy candidate.
Researchers from Salarius Pharmaceuticals Inc. have presented preclinical data on SP-3164, a novel cereblon (CRBN)-binding protein degrader intended for the treatment of lymphoma. SP-3164 bound to cereblon and consequently induced the degradation of hematological transcription factors Ikaros and Aiolos. The aim of their studies was to investigate the drug’s antitumor efficacy in preclinical models of diffuse large B-cell lymphoma (DLBCL).
Vega Therapeutics Inc. has reported promising preclinical data on VGA-039, a first-in-class monoclonal antibody directed against human protein S (ProS) that inhibits ProS cofactor activity for tissue factor pathway inhibitor α (TFPIα) and activated protein C (aPC), thus enhancing thrombin generation by acting on both the initiation (TFPIα) and propagation (aPC) phases of coagulation for potential activity against various bleeding disorders.
Treatment with anti-CD19 bispecific T-cell engager and CAR T therapies can lead to T-cell exhaustion and treatment failure. Novartis AG’s first-in-class anti-CD19, anti-CD3 and anti-CD2 IgG-like trispecific antibody PIT-565, which engages CD19+ on tumor cells, and CD3 (TCR signaling component) and CD2 (a costimulatory receptor) on T cells simultaneously to redirect T-cell cytotoxicity toward CD19-positive malignant B cells, has been designed to avoid T-cell exhaustion.
After gaining U.S. FDA priority approval for the first gene therapy to treat hemophilia B, CSL Ltd. reported long-term data from the pivotal HOPE-B trial that showed a single infusion of Hemgenix (etranacogene dezaparvovec-drlb) generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding.
At the ESMO Immuno-Oncology Congress 2022, Compugen Inc. shared phase I data for COM-701 in dual and triple combination with Bristol Meyers Squibb Co.’s Opdivo (nivolumab) and with or without BMS-986207.
New and updated clinical data presented by biopharma firms at the American Society of Hematology annual meeting and exposition, including: Abbvie, Actinium, Adicet, Affimed, Agios, Alphamab, Aptose, Argenx, Ascentage, Bellicum, Blueprint, BMS, Cellcentric, Cogent, CSL, CTI, Ellipses, Excellthera, Fate, Genentech.
New and updated preclinical data presented at the American Society of Hematology Annual Meeting in New Orleans, by: Ajax Therapeutics, Biomea Fusion, Cimeio Therapeutics, Fate Therapeutics, Graphite Bio, GT Biopharma, Ichnos Sciences, IGM Biosciences, Incyte, Kronos Bio, Kymera Therapeutics, Monopar Therapeutics, Orum Therapeutics, OSE Immunotherapeutics, Poseida Therapeutics, Puretech Health, Schrödinger, Senti Biosciences, Vincerx Pharma, Wugen.
Preliminary preclinical data have been reported for Enliven Therapeutics Inc.’s ATP-competitive small-molecule ABL1 tyrosine kinase inhibitor (TKI) ELVN-001. In vitro antiproliferative effects, assessed using the biomarker Tyr207-phosphorylated CRKL, demonstrated that ELVN-001 had potent activity with IC50 values ranging from 19 to 112 nM against BCR-ABL1-driven chronic myeloid leukemia (CML) cell lines in the presence of 50% to 100% human serum.
RSS
